Education
About Us
Working with TipRanks
Follow Us
Biocept, Inc. (BIOCQ)
:BIOCQ
Total Valuation
Biocept has a market cap or net worth of $263.00. The enterprise value is ―.
Market Cap$263.00
Enterprise Value―
Share Statistics
Biocept has 2,626,026 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,626,026
Owned by Insiders―
Owned by Institutions5.00%
Financial Efficiency
Biocept’s return on equity (ROE) is -3.62 and return on invested capital (ROIC) is -117.56%.
Return on Equity (ROE)-3.62
Return on Assets (ROA)-1.04
Return on Invested Capital (ROIC)-117.56%
Return on Capital Employed (ROCE)-1.26
Revenue Per Employee517.16K
Profits Per Employee-641.74K
Employee Count50
Asset Turnover0.84
Inventory Turnover37.57
Valuation Ratios
The current PE Ratio of Biocept is -0.09. Biocept’s PEG ratio is ―.
PE Ratio-0.09
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value0.34
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio―
Income Statement
In the last 12 months, Biocept had revenue of 25.86M and earned -32.09M in profits. Earnings per share was -56.78.
Revenue25.86M
Gross Profit-2.58M
Operating Income-31.98M
Pretax Income-32.21M
Net Income-32.09M
EBITDA-30.24M
Earnings Per Share (EPS)-56.78
Cash Flow
In the last 12 months, operating cash flow was -17.60M and capital expenditures -680.00K, giving a free cash flow of -18.28M billion.
Operating Cash Flow-17.60M
Free Cash Flow-18.28M
Free Cash Flow per Share-6.96
Dividends & Yields
Biocept pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-59.19
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)987.00
Important Dates
Biocept upcoming earnings date is Aug 12, 2024, TBA Not Confirmed.
Last Earnings DateMay 15, 2024
Next Earnings DateAug 12, 2024
Ex-Dividend Date―
Financial Position
Biocept as a current ratio of 2.97, with Debt / Equity ratio of 136.67%
Current Ratio2.97
Quick Ratio2.83
Debt to Market Cap0.04
Net Debt to EBITDA0.03
Interest Coverage Ratio-101.21
Taxes
In the past 12 months, Biocept has paid -125.00K in taxes.
Income Tax-125.00K
Effective Tax Rate<0.01
Enterprise Valuation
Biocept EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -0.16.
EV to Sales0.09
EV to EBITDA-0.07
EV to Free Cash Flow-0.16
EV to Operating Cash Flow-0.17
Balance Sheet
Biocept has $6.63M in cash and marketable securities with $11.59M in debt, giving a net cash position of $4.96M billion.
Cash & Marketable Securities$6.63M
Total Debt$11.59M
Net Cash$4.96M
Net Cash Per Share$1.89
Tangible Book Value Per Share$15.68
Margins
Gross margin is -9.99%, with operating margin of -123.69%, and net profit margin of -124.09%.
Gross Margin-9.99%
Operating Margin-123.69%
Pretax Margin-124.57%
Net Profit Margin-124.09%
EBITDA Margin-116.95%
EBIT Margin-123.35%
Analyst Forecast
The average price target for Biocept is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―